NCT01037309 - Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

May 31, 2013

Study Completion Date

October 31, 2013

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

PRO044 SC

Subcutaneous injection, once a week, for five weeks

DRUG

PRO044 IV

Intravenous injection, once a week, for five weeks

Trial Locations (4)

Leiden University Medical Center, Leiden

UZ Leuven, Leuven

S.Anna Hospital, Ferrara

The Queen Silvia Children's Hospital, Gothenburg